Bone Biologics Corporation (BBLG)

USD 0.71

(-17.43%)

Market Cap (In USD)

2.32 Million

Revenue (In USD)

-

Net Income (In USD)

-8.94 Million

Avg. Volume

180.95 Thousand

Currency
USD
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
0.8-10.56
PE
-0.15
EPS
-4.83
Beta Value
0.736
ISIN
US0980705018
CUSIP
098070303
CIK
1419554
Shares
3271041.0
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Medical - Devices
CEO
Mr. Jeffrey Frelick
Employee Count
-
Website
https://www.bonebiologics.com
Ipo Date
2021-10-13
Details
Bone Biologics Corporation, a medical device company, focuses on bone regeneration in spinal fusion using the recombinant human protein. The company's NELL-1/DBX is a combination product, which is an osteostimulative recombinant protein that provides target specific control over bone regeneration. It is developing NELL-1/DBX Fusion Device for spinal fusion procedures in skeletally mature patients with degenerative disc disease at one level from L4-S1. The company's platform technology has application in delivering enhanced outcomes in the surgical specialties of spinal, orthopedic, general orthopedic, plastic reconstruction, neurosurgery, interventional radiology, and sports medicine. It has a license agreement with the UCLA Technology Development Group to develop and commercialize NELL-1 for spinal fusion applications. The company was founded in 2004 and is headquartered in Burlington, Massachusetts.